Veradermics will report Part A topline results from study 304, a 536-participant phase 3 trial of VDPHL01, an extended-release oral minoxidil formulation for mild-to-moderate pattern hair loss. The company states the formulation blunts the high peak plasma concentrations associated with immediate-release oral minoxidil while prolonging time above the threshold associated with hair growth. Co-primary endpoints at month 6 are change in non-vellus target area hair count and participant-reported improvement on the AAIRS scale.
Key Points
- Phase 3 study 304 enrolled 536 men with pattern hair loss
- Extended-release design lowers peak plasma minoxidil, extends therapeutic exposure
- Three-trial program exceeds 1,600 adults across 52-week designs
Longevity Analysis
Reformulating an established vasodilator to flatten its concentration curve addresses a recurring problem in long-term therapeutics: the systemic cost of peak exposure often limits the duration a compound can be used. Hair follicle regeneration depends on sustained perfusion and uninterrupted cycling, which favors steady exposure over intermittent high concentrations — the same logic that governs dosing strategy across most interventions intended for years rather than weeks. Topline data at six months will indicate whether a pharmacokinetic refinement alone can convert an off-label practice into a validated, non-hormonal option that leaves androgen signaling untouched.
Original published by LT Wire.